Is This a Buying Opportunity for Zafgen?
It looks like Wednesday will be a huge day for Zafgen, considering the most recent development in the beloranib study.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 235
Aeterna Zentaris Rises on Finalized Marketing Agreement
Aeterna Zentaris announced that it has finalized of a co-marketing agreement with Armune BioScience that will allow it to promote Armune’s Apifiny.
Huge PowerShares ETF Rebalance Means Massive Buying for 4 Biotech Stocks
On the close Tuesday, the PowerShares Dynamic exchange traded funds (ETFs) are set for a rebalance. These four stocks that are expected to have huge buying on the close Tuesday.
Arena Pharma Soars on FDA Approval
Arena Pharmaceuticals saw its shares jump in Monday’s session on news of an U.S. Food and Drug Administration (FDA) approval.
Anavex Takes Off on Positive Alzheimer’s Data
Anavex Life Sciences announced the publication of further data for Anavex 3-71 in the peer-reviewed scientific journal Neurodegenerative Diseases.
4 Key FDA Decisions Expected By Year End
Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount of risk involved, as…
Short Sellers Run for Cover From Major Biotechs
24/7 Wall St. has reviewed the short interest data on the top biotech companies.
Merrill Lynch 4 Top Pharmaceutical Dividend Stocks To Own For 2016
Despite the howling from political candidates trying to make the top drug-makers their whipping boy in populist campaign efforts, the need and demand for pharmaceuticals will only continue. This is especially the case when you…
Analysts Start MyoKardia With Positive Ratings
MyoKardia, Inc. (NASDAQ: MYOK) has now moved far enough beyond the October 28 IPO pricing that the analysts in the underwriting syndicate can now begin their awaited analyst coverage. The end of the quiet…
Why Goldman Sachs Sees Serious Upside for Teva for 2016
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had a very hard time getting off the ground from 2011 through the start of 2014. This is the world’s top generic drug maker, and shares have gained…
Can-Fite Soars on Positive Phase 2 Developments
Biotech company Can-Fite announced development of its drug candidate CF102, which is currently in phase 2 trials for liver cancer, will be expanded into treatment for non-alcoholic steatohepatitis.
Mallinckrodt Impresses on Top and Bottom Line Results
Mallinckrodt PLC (NYSE: MNK) reported its fiscal fourth-quarter financial results before the markets opened on Monday. The company had $1.84 in earnings per share (EPS) on $882.4 million in revenue compared to consensus estimates…
6 BioHealth Movers That Now Cannot Be Ignored
24/7 Wall St. examines Valeant Pharmaceuticals and other biotech stocks with incredible gains or losses over the course of the past week.
Biotech Industry Study Reports Big Gains in M&A, IPOs
Consulting firm BDO USA's "2015 BDO Biotech Briefing" examined recent annual report filings of stocks included on the Nasdaq Biotechnology Index.
Anthem Affirms Guidance
Anthem is trying to convey the message that the problems of UnitedHealth Group are not its problem. At least that is what the company's guidance suggests.